Boehringer Ingelheim Corporation's Pradaxa Topped FDA Side Effect Reports

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

Will the bleeding stop? Last year, the FDA concluded that bleeding rates associated with Pradaxa, a relatively new bloodthinner, were no higher than among patients given warfarin, a decades-old medical standard. The assessment was designed to allay concerns that Pradaxa, which is used to reduce the risk of stroke and blood clots in patients with atrial fibrillation, but has been linked to hundreds of deaths.

Help employers find you! Check out all the jobs and post your resume.

Back to news